MS275 induces tumor immunosuppression by upregulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04004-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Deng Tang und 9 weiteren Autor:innen. Beteiligte Einrichtung: West China School of Basic Medical Science and Forensic Medicine, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China.
Abstract (Originalsprache)
The histone deacetylase inhibitor MS275 (Entinostat) demonstrates anti-tumor effects against various types of solid tumors in vitro. But its effectiveness in clinical trials is limited. The underlying reasons remain to be determined. The purpose of this study was to explore how to enhance the anti-tumor effects of MS275 in colorectal cancer (CRC). Our data showed that MS275 inhibited CRC cell proliferation and induced apoptosis, irrespective of gene mutation status. However, MS275 did not effectively suppress tumor growth in the AOM-DSS CRC model as observed in vitro. MS275 decreased CD3+T cell tumor infiltration and created an immunosuppressive microenvironment in the AOM-DSS CRC model. MS275 also decreased the percentage of CD8+T cells while increasing the percentage of CD4+T cells in mesenteric lymph nodes. Reshaping tumor immune response may contribute to the less pronounced anti-tumor effect of MS275 observed in vivo compared to in vitro. Further study showed that the increased PD-L1 expression in CRC both in vivo and in vitro following MS275 treatment. Moreover, the anti-tumor effects of MS275 were enhanced by combining it with an anti-PD-1 antibody. This combination treatment also increased CD8+T cell tumor infiltration in the AOM-DSS CRC model, thereby leading to an anti-tumor immune response. Therefore, the combination of MS275 and anti-PD-1 immunotherapy represents a potential strategy for low PD-L1 expression tumors and should be considered a promising treatment approach for colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- West China School of Basic Medical Science and Forensic Medicine, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
- Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
- West China School of Basic Medical Science and Forensic Medicine, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China. zhangj@scu.edu.cn.
- West China School of Basic Medical Science and Forensic Medicine, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China. wangyufang@scu.edu.cn.
Förderung
- the National Natural Science Foundation of China
Zitieren
APA
Tang, D., Mao, Z., Chen, S., Su, M., Lan, S., Yan, R., Xiang, Q., Zhao, X., Zhang, J., & Wang, Y. (2025). MS275 induces tumor immunosuppression by upregulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04004-4
Vancouver
Tang D, Mao Z, Chen S, Su M, Lan S, Yan R, et al. MS275 induces tumor immunosuppression by upregulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04004-4
BibTeX
@article{Tang2025,
author = {Tang, Deng and Mao, Zhigang and Chen, Sihan and Su, Mi and Lan, Siqi and Yan, Ruiting and Xiang, Qi and Zhao, Xianxian and Zhang, Ji and Wang, Yufang},
title = {MS275 induces tumor immunosuppression by upregulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04004-4}
}
EUVIMED